EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Florent Amatore iD, Madeleine Neildez, Adèle de Masson iD, Maxime Battistella, Marie Tauber, Saskia Ingen-Housz-Oro iD, Catherine Droitcourt iD, Delphine Staumont-Sallé, Marie Beylot-Barry iD

Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1344-1358

DOI: 10.1111/jdv.70407 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 12.03.2026. Verfasst von Florent Amatore und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, North Hospital, Assistance-Publique Hôpitaux de Marseille, INSERM U1068, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T‐cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous.

Objectives

To characterize the clinical features, timeline and outcomes of dupilumab‐related CTCL emergence in order to develop consensus‐based recommendations for dupilumab use in CTCL‐related settings.

Methods

A systematic review was conducted involving 51 studies reporting cases of CTCL in patients treated with dupilumab, followed by a modified delphi process to generate expert consensus recommendations.

Results

Data were obtained from 547 patients (mean age: 58 years; SD: 11.5; range: 10–85). New or worsening skin lesions were reported after dupilumab initiation, occurring at a mean of 8.9 months (SD 5.1; range 0.5–27 months). These were diagnosed as MF in 72% of cases, SS in 11% and other CTCL subtypes in 19%, of which 53% were at an early stage (stage ≤IIA). Dupilumab was discontinued in 75% of cases, and 62% received CTCL‐directed treatment. Clinical remission was achieved in 44 of the 63 patients with available follow‐up. The expert panel reached broad consensus, agreeing that dupilumab may unmask or exacerbate pre‐existing CTCL and should be avoided in cases of MF/SS and mogamulizumab‐induced rashes. They emphasized the importance of diagnostic vigilance, providing recommendations for skin biopsy, histology and clonality testing before and during treatment, particularly for patients with AD onset after the age of 40 or with atypical features. Dupilumab should be discontinued once CTCL confirmed, and methotrexate or phototherapy considered as alternatives. Cyclosporine and JAK inhibitors are considered unsuitable, and switching to other Th2‐targeting biologics is discouraged due to insufficient data.

Conclusions

Dupilumab may unmask or exacerbate CTCL, particularly MF and SS. The consensus‐based recommendations offer practical guidance for the safe management of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicLymphoma, T-Cell, CutaneousSkin NeoplasmsHumansMycosis FungoidesSezary Syndrome

Stichwörter der Autor:innen

DupilumabSézary syndromeatopic dermatitiscutaneous T‐cell lymphomasinterleukin 13mycosis fungoidessystematic review

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, North Hospital, Assistance-Publique Hôpitaux de Marseille, INSERM U1068, Aix-Marseille University, Marseille, France.
  • French Cutaneous Lymphoma Group (GFELC), From Société Française de Dermatologie (SFD), Paris, France.
  • Department of Dermatology, CHU Rennes, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail) UMR_S, Rennes, France.
  • Department of Dermatology, Saint-Louis University Hospital, AP-HP, Université Paris Cité, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France.
  • Pathology Department, Hôpital Saint-Louis, AP-HP, Paris, France.
  • Université Paris Cité, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France.

ORCID-Profile: Florent Amatore, Adèle de Masson, Saskia Ingen-Housz-Oro, Catherine Droitcourt, Marie Beylot-Barry

Zitieren

APA

Amatore, F., Neildez, M., de Masson, A., Battistella, M., Tauber, M., Ingen-Housz-Oro, S., Droitcourt, C., Staumont-Sallé, D., & Beylot-Barry, M. (2026). Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. Journal of the European Academy of Dermatology and Venereology, 40(8), 1344-1358. https://doi.org/10.1111/jdv.70407

Vancouver

Amatore F, Neildez M, de Masson A, Battistella M, Tauber M, Ingen-Housz-Oro S, et al. Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1344-1358. doi:10.1111/jdv.70407

BibTeX
@article{Amatore2026,
  author = {Amatore, Florent and Neildez, Madeleine and de Masson, Adèle and Battistella, Maxime and Tauber, Marie and Ingen-Housz-Oro, Saskia and Droitcourt, Catherine and Staumont-Sallé, Delphine and Beylot-Barry, Marie},
  title = {Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {1344--1358},
  doi = {10.1111/jdv.70407}
}
Kostenlos starten →